Comparing Appili Therapeutics (OTCMKTS:APLIF) & Elanco Animal Health (NYSE:ELAN)

Elanco Animal Health (NYSE:ELAN) and Appili Therapeutics (OTCMKTS:APLIF) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership and analyst recommendations.

Volatility & Risk

Elanco Animal Health has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500. Comparatively, Appili Therapeutics has a beta of -0.48, indicating that its share price is 148% less volatile than the S&P 500.

Profitability

This table compares Elanco Animal Health and Appili Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	4.60%	6.78%	3.03%
Appili Therapeutics	-450.64%	N/A	-187.38%

Insider & Institutional Ownership

97.5% of Elanco Animal Health shares are owned by institutional investors. 0.6% of Elanco Animal Health shares are owned by insiders. Comparatively, 11.8% of Appili Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Elanco Animal Health and Appili Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1	4	3	0	2.25
Appili Therapeutics	0	0	0	0	0.00

Elanco Animal Health presently has a consensus price target of $16.57, suggesting a potential upside of 32.57%. Given Elanco Animal Health’s stronger consensus rating and higher probable upside, research analysts plainly believe Elanco Animal Health is more favorable than Appili Therapeutics.

Earnings and Valuation

This table compares Elanco Animal Health and Appili Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.42 billion	1.40	-$1.23 billion	$0.40	31.25
Appili Therapeutics	$630,000.00	N/A	-$2.80 million	($0.02)	-1.27

Appili Therapeutics has lower revenue, but higher earnings than Elanco Animal Health. Appili Therapeutics is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Summary

Elanco Animal Health beats Appili Therapeutics on 11 of the 13 factors compared between the two stocks.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

About Appili Therapeutics

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.